Bristol-Myers Squibb Targets Mid-year Filing For Saxagliptin

Bristol and AstraZeneca reveal Onglyza brand name, positive monotherapy data for the DPP-4 inhibitor at American Diabetes Association meeting.

More from Archive

More from Pink Sheet